AIMP2 and glioblastoma: Our collective results from the retrospective clinical trial analysis suggest that AIMP2 expression may be the strongest candidate for predicting antiangiogenesis treatment response; thus, we emphasize on the applicability of AIMP2-cg04317940 as a stratifying factor in bevacizumab treatment response in TCGA-GBM (n = 80) and TCGA-LGG (n = 47).